Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A. Viktorsson K, et al. Among authors: holmsten k. Mol Oncol. 2016 May;10(5):719-34. doi: 10.1016/j.molonc.2015.12.013. Epub 2016 Jan 2. Mol Oncol. 2016. PMID: 26827254 Free PMC article.
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K, Jensen NV, Mouritsen LS, Jonsson E, Mellnert C, Agerbæk M, Nilsson C, Moe M, Carus A, Öfverholm E, Lahdenperä O, Brandberg Y, Johansson H, Hellström M, Maase HV, Pappot H, Ullén A. Holmsten K, et al. Eur J Cancer. 2020 Mar;127:173-182. doi: 10.1016/j.ejca.2019.08.033. Epub 2019 Oct 22. Eur J Cancer. 2020. PMID: 31648851 Free article. Clinical Trial.
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
Sjödahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, Johansson I, Kollberg P, Lindh C, Lövgren K, Marzouka NA, Olsson H, Höglund M, Ullén A, Liedberg F. Sjödahl G, et al. Among authors: holmsten k. Eur Urol. 2022 May;81(5):523-532. doi: 10.1016/j.eururo.2021.10.035. Epub 2021 Nov 13. Eur Urol. 2022. PMID: 34782206 Free article.
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjödahl G, Abrahamsson J, Holmsten K, Bernardo C, Eriksson P, Kollberg P, Marzouka NA, Höglund M, Ullén A, Liedberg F. Sjödahl G, et al. Among authors: holmsten k. Eur Urol. 2022 Apr;81(4):e92-e93. doi: 10.1016/j.eururo.2021.12.035. Epub 2022 Jan 14. Eur Urol. 2022. PMID: 35039183 No abstract available.
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K, Eknert J, Öfverholm E, Papantoniou D, Jawdat F, Verbiéné I, Laurell A, Jänes E, Sandzén J, Wojtyna-Dziedzic E, Lagstam I, Söderkvist K, Costa Svedman F, Liedberg F, Bruzelius M, Fransson AS, Kjellström S, Omland LH, Pappot H, Ullén A. Holmsten K, et al. Clin Genitourin Cancer. 2023 Dec;21(6):e438-e448. doi: 10.1016/j.clgc.2023.05.008. Epub 2023 May 17. Clin Genitourin Cancer. 2023. PMID: 37308329 Free article.
14 results